Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Receivables: 2009-2017

Historic Receivables for Northwest Biotherapeutics (NWBO) over the last 1 years, with Dec 2017 value amounting to $3.8 million.

  • Northwest Biotherapeutics' Receivables changed negligibly% to $3.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $14.7 million, marking a year-over-year increase of 103.46%. This contributed to the annual value of $3.8 million for FY2017, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Receivables of $3.8 million as of Q4 2017, which was down 0.00% from $3.8 million recorded in Q2 2017.
  • Over the past 5 years, Northwest Biotherapeutics' Receivables peaked at $3.8 million during Q4 2016, and registered a low of $3.8 million during Q4 2016.
  • Its 2-year average for Receivables is $3.8 million, with a median of $3.8 million in 2017.